Skip to main navigation
About Axsome
About Axsome
All
All
Overview
Management Team
Board of Directors
Intellectual Property
State Disclosures
Portfolio
Portfolio
All
All
Overview
Products Overview
Products Overview
All
All
Overview
Auvelity® (dextromethorphan-bupropion)
Sunosi® (solriamfetol)
Symbravo® (meloxicam and rizatriptan)
Pipeline Overview
Pipeline Overview
All
All
Overview
AXS-05
AXS-12
AXS-14
Conditions
Conditions
All
All
Overview
Depression
Migraine
Alzheimer’s Disease Agitation
Excessive Daytime Sleepiness
Narcolepsy
Fibromyalgia
Smoking Cessation
Science
Science
All
All
Overview
Medical Information U.S.
Medical Information Canada
Publications
Investors
Investors
All
All
Overview
Corporate Governance
Stock Information
Financial Information
News & Events
Webcasts & Presentations
Analyst Coverage
Shareholder Services
Careers
Careers
All
All
Overview
Current Opportunities
Event Details
Event
Details
Event Details
News Releases
Events
Axsome Fourth Quarter 2025 Financial Results
February 23, 2026 at 8:00 AM EST
Click here for webcast
